NVCT - Nuvectis Pharma, Inc. Stock Price, Fair Value and News

$4.52-0.17 (-3.62%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NVCT Price Action

Last 7 days

-3.8%

Last 30 days

-10.8%

Last 90 days

-30.5%

Trailing 12 Months

-44.0%

NVCT RSI Chart

NVCT Valuation

Market Cap

87.3M

Price/Earnings (Trailing)

-4.51

Price/Sales (Trailing)

98.12

Price/Free Cashflow

-6.41

NVCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NVCT Fundamentals

NVCT Revenue

Revenue (TTM)

890.0K

Rev. Growth (Yr)

-25.63%

Rev. Growth (Qtr)

-4.19%

NVCT Earnings

Earnings (TTM)

-19.4M

Earnings Growth (Yr)

29.38%

Earnings Growth (Qtr)

6.21%

NVCT Profitability

Return on Equity

-176.27%

Return on Assets

-111.94%

Free Cashflow Yield

-15.61%

NVCT Investor Care

Shares Dilution (1Y)

11.51%

Diluted EPS (TTM)

-1.16

NVCT Alerts

2 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	810.0K	961.0K	890.0K	0
2023	199.0K	259.0K	475.0K	637.0K
2022	40.3K	76.5K	112.8K	149.0K
2021	0	0	0	4.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

CEO	Mr. Ron Bentsur M.B.A.
WEBSITE	nuvectis.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	11

Nuvectis Pharma, Inc. Frequently Asked Questions

What is the ticker symbol for Nuvectis Pharma, Inc.? What does NVCT stand for in stocks?

NVCT is the stock ticker symbol of Nuvectis Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuvectis Pharma, Inc. (NVCT)?

As of Fri Dec 20 2024, market cap of Nuvectis Pharma, Inc. is 87.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVCT stock?

You can check NVCT's fair value in chart for subscribers.

Is Nuvectis Pharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether NVCT is over valued or under valued. Whether Nuvectis Pharma, Inc. is cheap or expensive depends on the assumptions which impact Nuvectis Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVCT.

What is Nuvectis Pharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, NVCT's PE ratio (Price to Earnings) is -4.51 and Price to Sales (PS) ratio is 98.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCT PE ratio will change depending on the future growth rate expectations of investors.